{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:21:50Z","timestamp":1790256110188,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10689-020-00195-0","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T02:02:31Z","timestamp":1594778551000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report"],"prefix":"10.1007","volume":"20","author":[{"given":"Yasuhiro","family":"Iribe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-8179","authenticated-orcid":false,"given":"Mitsuko","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hasumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Nakaigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"issue":"5","key":"195_CR1","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1086\/320124","volume":"68","author":"NA Alam","year":"2001","unstructured":"Alam NA, Bevan S, Churchman M, Barclay E, Barker K, Jaeger EE, Nelson HM, Healy E, Pembroke AC, Friedmann PS, Dalziel K, Calonje E, Anderson J, August PJ, Davies MG, Felix R, Munro CS, Murdoch M, Rendall J, Kennedy S, Leigh IM, Kelsell DP, Tomlinson IP, Houlston RS (2001) Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 68(5):1264\u20131269. https:\/\/doi.org\/10.1086\/320124","journal-title":"Am J Hum Genet"},{"issue":"3","key":"195_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0002-9440(10)61757-9","volume":"159","author":"M Kiuru","year":"2001","unstructured":"Kiuru M, Launonen V, Hietala M, Aittomaki K, Vierimaa O, Salovaara R, Arola J, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 159(3):825\u2013829. doi:https:\/\/doi.org\/10.1016\/S0002-9440(10)61757-9","journal-title":"Am J Pathol"},{"issue":"6","key":"195_CR3","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1073\/pnas.051633798","volume":"98","author":"V Launonen","year":"2001","unstructured":"Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98(6):3387\u20133392. https:\/\/doi.org\/10.1073\/pnas.051633798","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"195_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA, Multiple Leiomyoma C (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4):406\u2013410. doi:https:\/\/doi.org\/10.1038\/ng849","journal-title":"Nat Genet"},{"issue":"4","key":"195_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","volume":"13","author":"FH Menko","year":"2014","unstructured":"Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomaki K, Tomlinson I, Richard S, Linehan WM (2014) Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 13(4):637\u2013644. https:\/\/doi.org\/10.1007\/s10689-014-9735-2","journal-title":"Fam Cancer"},{"issue":"1","key":"195_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol 70(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029","journal-title":"Eur Urol"},{"issue":"6","key":"195_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cge.13014","volume":"92","author":"M Muller","year":"2017","unstructured":"Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR (2017) Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Clin Genet 92(6):606\u2013615. doi:https:\/\/doi.org\/10.1111\/cge.13014","journal-title":"Clin Genet"},{"issue":"5","key":"195_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","volume":"38","author":"YB Chen","year":"2014","unstructured":"Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, Reuter VE (2014) Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 38(5):627\u2013637. doi:https:\/\/doi.org\/10.1097\/PAS.0000000000000163","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"195_CR9","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","volume":"31","author":"MJ Merino","year":"2007","unstructured":"Merino MJ, Torres-Cabala C, Pinto P, Linehan WM (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31(10):1578\u20131585. doi:https:\/\/doi.org\/10.1097\/PAS.0b013e31804375b8","journal-title":"Am J Surg Pathol"},{"issue":"34","key":"195_CR10","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794\u20135799. doi:https:\/\/doi.org\/10.1200\/JCO.2008.21.4809","journal-title":"J Clin Oncol"},{"issue":"2","key":"195_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. doi:https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"14","key":"195_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate I (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"5","key":"195_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grunwald V, Gillessen S, Horwich A, Committee EG (2019) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 30(5):706\u2013720. https:\/\/doi.org\/10.1093\/annonc\/mdz056","journal-title":"Ann Oncol"},{"issue":"5","key":"195_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A (2019) European Association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799\u2013810. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.011","journal-title":"Eur Urol"},{"issue":"3","key":"195_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","volume":"17","author":"AJ Armstrong","year":"2016","unstructured":"Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17(3):378\u2013388. doi:https:\/\/doi.org\/10.1016\/S1470-2045(15)00515-X","journal-title":"Lancet Oncol"},{"issue":"5","key":"195_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","volume":"69","author":"NM Tannir","year":"2016","unstructured":"Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK (2016) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 69(5):866\u2013874. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.049","journal-title":"Eur Urol"},{"issue":"5","key":"195_CR17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.eururo.2015.07.008","volume":"68","author":"DM Geynisman","year":"2015","unstructured":"Geynisman DM (2015) Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 68(5):912\u2013914. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.008","journal-title":"Eur Urol"},{"key":"195_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fonc.2016.00250","volume":"6","author":"J Ruiz-Banobre","year":"2016","unstructured":"Ruiz-Banobre J, Anido U, Abdulkader I, Antunez-Lopez J, Lopez-Lopez R, Garcia-Gonzalez J (2016) Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front Oncol 6:250. https:\/\/doi.org\/10.3389\/fonc.2016.00250","journal-title":"Front Oncol"},{"issue":"5","key":"195_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10637-017-0469-5","volume":"35","author":"DA Adrianzen Herrera","year":"2017","unstructured":"Adrianzen Herrera DA, Fleisig SB, Gartrell BA (2017) Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Invest New Drugs 35(5):665\u2013668. https:\/\/doi.org\/10.1007\/s10637-017-0469-5","journal-title":"Invest New Drugs"},{"issue":"7","key":"195_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2019.37.7_suppl.546","volume":"37","author":"DF McDermott","year":"2019","unstructured":"McDermott DF, Lee J-L, Ziobro M, Gafanov R, Matveev VB, Suarez C, Donskov F, Pouliot F, Alekseev BY, Wiechno PJ, Tomczak P, Duran MAC, Shin SJ, Silverman RK, Perini RF, Schloss C, Atkins MB (2019) First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): results from KEYNOTE-427 cohort B. J Clin Oncol 37(7):1. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.546","journal-title":"J Clin Oncol"},{"issue":"1","key":"195_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","volume":"7","author":"BI Rini","year":"2019","unstructured":"Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer 7(1):354. doi:https:\/\/doi.org\/10.1186\/s40425-019-0813-8","journal-title":"J Immunother Cancer"},{"issue":"4","key":"195_CR22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4143\/crt.2019.086","volume":"51","author":"Y Choi","year":"2019","unstructured":"Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL (2019) Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in korean patients. Cancer Res Treat 51(4):1549-1556. https:\/\/doi.org\/10.4143\/crt.2019.086","journal-title":"Cancer Res Treat"},{"key":"195_CR23","doi-asserted-by":"crossref","unstructured":"Srinivasan R, Gurram S, Al Harthy M, Singer EA, Sidana A, Shuch BM, Ball MW, Friend JC, Mac L, Purcell E, Vocke C, Kong HH, Cowen EW, Choyke PL, Malayeri AA, Long L, Shih JH, Merino MJ, Linehan MW (2020) Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol 38:5004 (15_suppl). https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2020.38.15_suppl.5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004"},{"issue":"1","key":"195_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12894-019-0484-2","volume":"19","author":"I Park","year":"2019","unstructured":"Park I, Shim YS, Go H, Hong BS, Lee JL (2019) Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol 19(1):51. doi:https:\/\/doi.org\/10.1186\/s12894-019-0484-2","journal-title":"BMC Urol"},{"key":"195_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.anndiagpath.2017.04.007","volume":"29","author":"R Alaghehbandan","year":"2017","unstructured":"Alaghehbandan R, Stehlik J, Trpkov K, Magi-Galluzzi C, Condom Mundo E, Pane Foix M, Berney D, Sibony M, Suster S, Agaimy A, Montiel DP, Pivovarcikova K, Michalova K, Daum O, Ondic O, Rotterova P, Dusek M, Hora M, Michal M, Hes O (2017) Programmed death-1 (PD-1) receptor\/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol 29:17\u201322. doi:https:\/\/doi.org\/10.1016\/j.anndiagpath.2017.04.007","journal-title":"Ann Diagn Pathol"},{"issue":"11","key":"195_CR26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139\u20132145. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0255","journal-title":"Cancer Res"},{"issue":"9","key":"195_CR27","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107(9):4275\u20134280. https:\/\/doi.org\/10.1073\/pnas.0915174107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"195_CR28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194(3):950\u2013959. doi:https:\/\/doi.org\/10.4049\/jimmunol.1401686","journal-title":"J Immunol"},{"issue":"1","key":"195_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.19.01882","volume":"38","author":"BA McGregor","year":"2020","unstructured":"McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, Choueiri TK (2020) Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features. J Clin Oncol 38(1):63\u201370. https:\/\/doi.org\/10.1200\/JCO.19.01882","journal-title":"J Clin Oncol"},{"issue":"12","key":"195_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, Investigators K- (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"12","key":"195_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-020-00195-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00195-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T23:26:11Z","timestamp":1626305171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-020-00195-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1007\/s10689-020-00195-0","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}